Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 4 of the 15 sources its claims cite were checked for support.
Abstract
The nuclear-encoded Krebs cycle enzymes, fumarate hydratase (FH) and succinate dehydrogenase (SDHB, -C and -D), act as tumour suppressors. Germline mutations in FH predispose individuals to leiomyomas and renal cell cancer (HLRCC), whereas mutations in SDH cause paragangliomas and phaeochromocytomas (HPGL). In this study, we have shown that FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate. SDH-deficient tumours principally accumulate succinate. In situ analyses showed that these tumours also have over-expression of hypoxia-inducible factor 1alpha (HIF1alpha), activation of HIF1alphatargets (such as vascular endothelial growth factor) and high microvessel density. We found no evidence of increased reactive oxygen species in our cells. Our data provide in vivo evidence to support the hypothesis that increased succinate and/or fumarate causes stabilization of HIF1alpha a plausible mechanism, inhibition of HIF prolyl hydroxylases, has previously been suggested by in vitro studies. The basic mechanism of tumorigenesis in HPGL and HLRCC is likely to be pseudo-hypoxic drive, just as it is in von Hippel-Lindau syndrome.
Overview
CoChat Summary
TL;DR
This study provides in vivo evidence that germline FH and SDH mutations lead to accumulation of Krebs cycle intermediates and HIF1α over-expression in HLRCC and HPGL tumours, supporting pseudo-hypoxic drive as a shared tumorigenic mechanism. It also finds no evidence of increased reactive oxygen species in FH-deficient cells.
Key findings
- FH-deficient fibroblasts and HLRCC fibroids accumulate fumarate and succinate. FH-deficient fibroblast succinate was mean 59.4 mmol/g protein (median 39.8, range 32–125.9) versus controls mean 17.4 (median 14.5, range 9.9–29.8); HLRCC fibroids had succinate 70–98 and fumarate 417–688 mmol/g protein, with succinate:fumarate ratios of 0.10–0.22 versus >1 in myometria.
- SDH-deficient HPGL tumours principally accumulate succinate. SDHB-mutant paragangliomas had succinate 364.5 and 517.0 mmol/g protein versus non-HPGL tumours 32.3–49.7; one SDHB tumour (patient 4) did not show elevated succinate.
- HIF1α over-expression and HIF-target activation were seen in tumours: strong nuclear HIF1α in all HPGL tumours studied (12 paragangliomas and 4 phaeochromocytomas), moderate staining in HLRCC fibroids, and very strong staining in three renal cancers; VEGF expression was high and CD34 showed high microvessel density. Western blotting confirmed a 120 kDa HIF1α band only in tumour, not normal kidney.
- No notable increase in oxidative stress was found: SOD mean was 44.4 versus 38.2 mU/mg and reduced glutathione mean was 5.52 versus 4.04 nmol/mg in FH-deficient versus control cells, with retained mitochondrial complex I, II–III and IV activities.
Methods
- Metabolomic profiling used 1H MRS on skin fibroblasts from four fumarase deficiency patients and six controls, and GC/MS on frozen HLRCC fibroids, myometrium controls, and frozen paragangliomas plus non-HPGL controls.
- Mutation screening of SDHB, SDHC and SDHD was performed by direct sequencing, with array CGH for allelic loss; tumour analyses included HIF1α and CD34 immunohistochemistry, VEGF in situ hybridization, and HIF1α western blotting.
- Samples included HLRCC fibroids and renal cancers, HPGL paragangliomas and phaeochromocytomas, and normal myometrium/kidney controls, all collected with Research Ethics Committee approval.
Limitations
- The paper states that formal statistical analysis was problematic given the small number of samples and lack of information on underlying factors; tumour scarcity also meant duplicate metabolite analysis was not possible.
- The paper notes that one SDHB tumour failed to show elevated succinate for unclear reasons, that HPGL versus other tumour succinate differences were only just significant (P = 0.045) owing to sample 3, and that direct PHD inhibition by fumarate in HLRCC cannot be excluded.
- Evident from the text: HIF1α staining was also weak/moderate in surrounding myometrium, and the oxidative-stress conclusion rests on only two FH-deficient lines for SOD/glutathione assays.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 7 Not checked · 67 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“germline mutations in the B, C and D subunits of SDH predispose individuals to hereditary paragangliomatosis with phaeochromocytomas (HPGL) (2 -6)”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > INTRODUCTION
What the sources say
- Not checked yetcites [2] Baysal, B.E., Ferrell, R.E., Willett-Brozick, J.E., Lawrence, E.C., Myssiorek, D., Bosch, A., van der Mey, A., Taschner, P.E., Rubinstein, W.S., Myers, E.N. et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 287, 848-851. source
- Not checked yetcites [3] Gimm, O., Armanios, M., Dziema, H., Neumann, H.P. and Eng, C. (2000) Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res., 60, 6822-6825.
- Not checked yetcites [4] Niemann, S. and Muller, U. (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet., 26, 268-270. source
- Partly supportedcites [5] Astuti, D., Latif, F., Dallol, A., Dahia, P.L., Douglas, F., George, E., Skoldberg, F., Husebye, E.S., Eng, C. and Maher, E.R. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet., 69, 49-54. sourceExperimental — accuracy not yet measured
The Abstract and Results of Astuti et al. (2001) support the SDHB component strongly: inactivating germline SDHB mutations were found in eight families 'segregating pheochromocytoma with or without head and neck paraganglioma' plus one occult germline case, and the SDHD association is stated as background ('pheochromocytoma susceptibility has been associated with germline SDHD mutations'). The SDHC component is not this paper's finding: the Results state 'No pathogenic mutations were identified in SDHC' and 'there was no evidence of germline SDHC mutations in the kindreds with familial pheochromocytoma and paraganglioma', with the SDHC link credited to Niemann and Muller (2000) in the Discussion, and the Abstract hedges that SDHC and SDHD mutations 'may cause hereditary paraganglioma'. So the composite claim (B, C and D, stated as established predisposition) overstates what this source reports for SDHC. (LLM, conf=0.78)
- Not checked yetcites [6] Astuti, D., Douglas, F., Lennard, T.W., Aligianis, I.A., Woodward, E.R., Evans, D.G., Eng, C., Latif, F. and Maher, E.R. (2001) Germline SDHD mutation in familial phaeochromocytoma. Lancet, 357, 1181-1182. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“neither our data nor those of Selak et al. (27) have provided evidence for an alternative model of tumorigenesis in HLRCC or HPGL based on increased levels of ROSs.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Partly supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. sourceExperimental — accuracy not yet measured
In “Reactive oxygen species do not play a role in HIF-1α induction after SDH inhibition” (page not available), Selak et al. report no detectable increase in ROS or change in glutathione redox state after SDH inhibition. That supports the statement as applied to the SDH-related HPGL model, but these data do not test the FH-related HLRCC model. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) showed that the mechanism for these findings may be inhibition by succinate of HIF PHDs, which rely for their activity on conversion of a-ketoglutarate to succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
The Introduction states that HIF prolyl hydroxylases use α-ketoglutarate and convert it to succinate during hydroxylation. In “Succinate is accumulated in SDH-inhibited cells,” the authors propose that accumulated succinate may inhibit this required reaction and impede PHD activity. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) tested a model of tumorigenesis in which raised levels of succinate caused increased HIF1a expression in vitro.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
In the section on succinate elevation and HIF-1α stabilization in cells (page unavailable), Selak et al. report that cells treated with a membrane-permeable succinate derivative had elevated HIF-1α levels under normoxic conditions. This supports the attributed in-vitro model; the measured increase was in HIF-1α protein levels, through stabilization. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 78 claims and to verify the 11 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 14
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevation of fumarate and succinate, such as in renal cancer subtypes bearing succinate dehydrogenase (SDH) or fumarate hydratase mutations, suppress HIF-α hydroxylation by the PHDs, resulting in the stabilization of both HIF-1α and HIF-2α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, unlike pVHL-deficient ccRCC tumors that constitutively express both HIF isoforms or HIF-2α preferentially, renal cancers bearing FH/SDH mutations tend to preferentially express HIF-1α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, succinate and fumarate inhibit the prolyl hydroxylase domain-containing (PHD) enzymes that regulate stability of hypoxia-inducible factors (HIFs), such that FH and SDH deficient cancers activate the hypoxic gene expression program even under normoxic conditions (Hewitson et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Pollard et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Pollard et al., 2005
In the citing paper
“For example, the increase in ROS induced by antimycin A can be abolished by adding either stigmatellin or myxothiazol (256).”
From Mitochondrial reactive oxygen species production in excitable cells: Modulators of mitochondrial and cell function (2009) · cites this paper as [256]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Increased succinate in HPGL tumours
“One SDHB tumour (patient 4) did not show elevated succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Western blotting
“| 4 | No | 32.3 | 3.0 | 10.8 |”
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“Mutations in VHL cause stabilization of the subunits of hypoxia-inducible factor (HIF) (18), which initiates the transcription of genes coding for pro-angiogenic proteins such as VEGF (19).”
BackgroundSuccinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 4×
“Recently, support has been provided using an in vitro system for dysfunction of the Krebs cycle leading to the stabilization of HIF (27).”
BackgroundInfluentialMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Self-citationTransition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383 · cited 1×
“Oxidative stress in FH-deficient and control cells was measured using a HPLC method to analyse the oxidation status of the antioxidant glutathione as previously described (33).”
Method[45] Cytochrome oxidase from beef heart mitochondria
Wharton, D. C., & Tzagoloff, A. (1967) · Methods in Enzymology · doi:10.1016/0076-6879(67)10048-7 · Cited by 1,261
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Architecture of succinate dehydrogenase and reactive oxygen species generation
Yankovskaya, V., Horsefield, R., Törnroth, S., Luna-Chavez, C., Miyoshi, H., Léger, C., Byrne, B., Cecchini, G., & Iwata, S. (2003) · Science · doi:10.1126/science.1079605 · Cited by 927
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893 · cited 1×
“SDHB mutations are associated with a higher proportion of malignant lesions and a relatively greater risk of phaeochromocytoma (8).”
Background
Cited by
Items 201–300 of 982
Fliedner, S. M. J., Lehnert, H., & Pacák, K. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.10.017 · Cited by 116
Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers
Chappell, J. C., Payne, L. B., & Rathmell, W. K. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120855 · Cited by 115
“Constitutive HIF stabilization further contributes to metabolic aberrance in this cancer (14, 15).”
BackgroundRelevance of Mitochondrial Genetics and Metabolism in Cancer Development
Gasparre, G., Porcelli, A. M., Lenaz, G., & Romeo, G. C. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a011411 · Cited by 116
Kerins, M. J., Milligan, J., Wohlschlegel, J. A., & Ooi, A. (2018) · Cancer Science · doi:10.1111/cas.13701 · Cited by 116
Lack of Hypoxic Response in Uterine Leiomyomas despite Severe Tissue Hypoxia
Mayer, A., Höckel, M., Wree, A., Leo, C., Horn, L., & Vaupel, P. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6339 · Cited by 113
SDH-related pheochromocytoma and paraganglioma
Kantorovich, V., King, K. S., & Pacák, K. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.04.001 · Cited by 113
Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation
Brière, J.-J., Favier, J., Gimenez-Roqueplo, A.-P., & Rustin, P. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00216.2006 · Cited by 109
“Recently, a very similar mechanism was described for FH deficiency in a renal cell cancer (28, 45).”
BackgroundSelf-citationEisenhofer, G., Klink, B., Richter, S., Lenders, J. W. M., & Robledo, M. (2017) · Europe PMC (PubMed Central) · Cited by 110
Forde, C., Lim, D., Alwan, Y., Burghel, G. J., Butland, L., Cleaver, R., Dixit, A., Evans, D. G., Hanson, H., Lalloo, F. I., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.11.002 · Cited by 110
Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects
Ferro, M., Musi, G., Marchioni, M., Maggi, M., Veccia, A., Giudice, F. D., Barone, B., Crocetto, F., Lasorsa, F. M., Antonelli, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054615 · Cited by 109
“SDH and FH (enzyme of Krebs cycle) loss leads to the accumulation of succinate and fumarate [124].”
BackgroundRichter, S., Gieldon, L., Pang, Y. K., Peitzsch, M., Huynh, T., Letón, R., Viana, B., Ercolino, T., Mangelis, A., Rapizzi, E., et al. (2018) · Genetics in Medicine · doi:10.1038/s41436-018-0106-5 · Cited by 110
Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies
Xiao, Y., & Meierhofer, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153672 · Cited by 107
Central carbon metabolism in the progression of mammary carcinoma
Richardson, A. D., Chen, Y., Osterman, A. L., & Smith, J. W. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9732-3 · Cited by 107
“In fact, germline mutations in either fumarate hydratase or succinate dehydrogenase can drive this event and lead to a predisposition to tumors [28].”
Background5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer
Kroeze, L. I., van der Reijden, B. A., & Jansen, J. H. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.001 · Cited by 107
SDHi fungicides: An example of mitotoxic pesticides targeting the succinate dehydrogenase complex
Tête, A., Debizet, K., Imler, J., Tomkiewicz, C., Blanc, É., Barouki, R., Coumoul, X., & Bortoli, S. (2023) · Environment International · doi:10.1016/j.envint.2023.108219 · Cited by 106
Post-translational modifications and their implications in cancer
Dutta, H., & Jain, N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1240115 · Cited by 107
Metabolic dysregulation in monogenic disorders and cancer — finding method in madness
Erez, A., & DeBerardinis, R. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3949 · Cited by 105
Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging
Alrezk, R., Suárez, A., Tena, I., & Pacák, K. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00515 · Cited by 105
“FH is a tumor suppressor gene in the TCA cycle that encodes FH enzyme, which converts fumarate into malate (31).”
BackgroundSzeto, S. S. W., Reinke, S. N., Sykes, B. D., & Lemire, B. D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700601200 · Cited by 104
Mitochondrial complex II, a novel target for anti-cancer agents
Kluckova, K., Bezawork-Geleta, A., Rohlena, J., Dong, L., & Neuzil, J. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.10.015 · Cited by 104
“It has been reported that the activity of CII in tumors bearing SDHA-D mutations is compromised [58-61].”
Keshari, K. R., Sriram, R., Koelsch, B. L., Criekinge, M. V., Wilson, D. M., Kurhanewicz, J. V., & Wang, Z. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-3461 · Cited by 104
“The reduced FH leads to accumulation of hypoxia inducible factor-2 alpha (HIF2α) (45), a transcription factor known to promote renal carcinogenesis in part by up-regulating glycolysis (17).”
Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells
Zheng, L., MacKenzie, E. D., Karim, S. A., Hedley, A., Blyth, K., Kalna, G., Watson, D. G., Szlosarek, P., Frezza, C., & Gottlieb, E. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-12 · Cited by 103
“The accumulation of fumarate was identified as one of the most striking biochemical features of FH-deficient cells, with a potential tumorigenic role [5,6].”
BackgroundTCA Cycle Rewiring as Emerging Metabolic Signature of Hepatocellular Carcinoma
Todisco, S., Convertini, P., Iacobazzi, V., & Infantino, V. (2019) · Cancers · doi:10.3390/cancers12010068 · Cited by 103
Clinical implications of the oncometabolite succinate in SDHx ‐mutation carriers
Eijkelenkamp, K., Osinga, T. E., Links, T. P., & van der Horst‐Schrivers, A. N. A. (2019) · Clinical Genetics · doi:10.1111/cge.13553 · Cited by 103
Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature
Türkoğlu, O., Zeb, A., Graham, S. F., Szyperski, T., Szender, J. B., Odunsi, K. O., & Bahado-Singh, R. O. (2016) · Metabolomics · doi:10.1007/s11306-016-0990-0 · Cited by 104
“The loss of their enzymatic activities increases the succinate and fumarate levels, correspondingly (Pollard et al. 2005).”
BackgroundMolecular Pathways: Metabolic Control of Histone Methylation and Gene Expression in Cancer
Tran, T. Q., Lowman, X. H., & Kong, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2506 · Cited by 103
“For example, loss-of-function mutations in the succinate dehydrogenase (SDH) gene and the fumarate hydratase (FH) gene are found in a number of human cancers that lead to rapid accumulation of succinate or fumarate (26, 27).”
BackgroundThe multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit?
Abla, H., Sollazzo, M., Gasparre, G., Iommarini, L., & Porcelli, A. M. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.031 · Cited by 103
Biochemical Assays for Mitochondrial Activity: Assays of TCA Cycle Enzymes and PDHc
Saada, A., & Elpeleg, O. N. (2007) · Methods in cell biology · doi:10.1016/s0091-679x(06)80010-5 · Cited by 103
MUC1: A novel metabolic master regulator
Mehla, K., & Singh, P. K. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.01.001 · Cited by 106
“High levels of succinate or fumarate, caused by succinate dehydrogenase (SDH) or fumarate hydratase (FH) inhibition/mutation, respectively, stabilize HIF-1α in cancer cells [64].”
BackgroundMoreno‐Sánchez, R., Hernández‐Esquivel, L., Rivero‐Segura, N. A., Marín‐Hernández, A., Neuzil, J., Ralph, S. J., & Rodríguez‐Enríquez, S. (2013) · The FEBS Journal · doi:10.1111/febs.12086 · Cited by 100
Alam, M. M., Lal, S., FitzGerald, K. E., & Li, Z. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0082-9 · Cited by 101
“In three cases of paragan-gliomatosis with SDH mutation, succinate accumulated to a high level of 364–517 μmol g − 1 protein [82].”
BackgroundHoekstra, A. S., de Graaff, M. A., Briaire-de Bruijn, I. H., Ras, C., Seifar, R. M., van Minderhout, I., Cornelisse, C. J., Hogendoorn, P. C. W., Breuning, M. H., Suijker, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6091 · Cited by 99
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1978-z · Cited by 99
Cells Silenced for SDHB Expression Display Characteristic Features of the Tumor Phenotype
Cervera, A. M., Apostolova, N., Crespo, F. L., Mata, M., & McCreath, K. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5580 · Cited by 98
Bénit, P., Letouzé, É., Rak, M., Aubry, L., Burnichon, N., Favier, J., Gimenez‐Roqueplo, A., & Rustin, P. (2014) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2014.03.013 · Cited by 98
Self-citationA role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia
Adam, J., Yang, M., Bauerschmidt, C., Kitagawa, M., O’Flaherty, L., Maheswaran, P., Özkan, G., Sahgal, N., Baban, D., Kato, K., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.006 · Cited by 97
“Loss of FH activity results in accumulation of intracellular fumarate, which, in turn, affects multiple signaling pathways, including inhibition of 2-oxoglutarate (2OG)-dependent dioxygenase enzymes (Isaacs et al., 2005; Loenarz and Schofield, 2008; O’Flaherty et al., 2010; Pollard et al., 2005; Xiao et al., 2012) and…”
BackgroundSelf-citationMitochondria as targets for cancer therapy
Ralph, S. J., & Neuzil, J. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200800044 · Cited by 97
Chicken or the egg: Warburg effect and mitochondrial dysfunction
Senyilmaz, D., & Teleman, A. A. (2015) · F1000Prime Reports · doi:10.12703/p7-41 · Cited by 99
“In the context of SHD and FH mutations, cytosolic succinate [106,107] and fumarate [108] concentrations increase and they inhibit the activity of PHDs, leading to stabilization of HIF1a (Figure 3A) even in the presence of oxygen and induction of an aberrant hypoxic response [109].”
BackgroundThe altered metabolism of tumors: HIF-1 and its role in the Warburg effect
Stubbs, M., & Griffiths, J. R. (2009) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2009.10.027 · Cited by 100
“…dehydratase and succinate dehydrogenase (associated with rare familial tumor syndromes) increase levels of fumarate or succinate respectively, and inhibit HIF-1a hydroxylation by competitively blocking the binding of 2-oxogluarate, thus activating HIF (Isaacs et al., 2005; Pollard et al., 2005).”
BackgroundSelf-citationDysregulated metabolic enzymes and metabolic�reprogramming in cancer cells (Review)
Sreedhar, A., & Zhao, Y. (2017) · Biomedical Reports · doi:10.3892/br.2017.1022 · Cited by 98
“Mutations in the enzyme SDH, which catalyzes the oxidation of succinate to fumarate, are implicated in pheochromocytoma, paraganglioma, renal cell carcinoma and papillary thyroid cancers (50-52).”
Merkley, E. D., Metz, T., Smith, R. D., Baynes, J., & Frizzell, N. (2013) · Mass Spectrometry Reviews · doi:10.1002/mas.21382 · Cited by 96
“Mutations in FH lead to elevated fumarate levels in these cancers (Pollard et al., 2005), and fumarate is increasingly recognized as an “oncometabolite” in HLRCC; a component of normal metabolism whose accumulation leads to metabolic dysregulation, priming cells for oncogenesis (Yang et al., 2012b).”
BackgroundThe twisted survivin connection to angiogenesis
Sanhueza, C. T., Wehinger, S., Bennett, J., Valenzuela, M., Owen, G. I., & Quest, A. F. G. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0467-1 · Cited by 93
“Multiple mitochondrial products, including TCA cycle intermediates, have been shown to favor HIF1α stabilization and cellular responses similar to those observed upon O2 depletion [37, 59] For instance, an increase in succinate levels in the absence of ROS in HEK cells leads to HIF1α stabilization and increased VEGF m…”
BackgroundInfluentialStructural basis of fumarate hydratase deficiency
Picaud, S., Kavanagh, K. L., Yue, W. W., Lee, W. H., Müller, S., Gileadi, O., Sacchettini, J. C., & Oppermann, U. C. T. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9294-8 · Cited by 92
“10 Pro174 Arg P174R c.521 C>G 4 Not conserved Surface (Alam et al. 2005b), (Zeng et al. 2006), ( Pollard et al. 2005 ) FHD”
Alchanati, I., Nallar, S. C., Sun, P., Gao, L., Hu, J., Stein, A., Yakirevich, E., Konforty, D., Alroy, I., Zhao, X., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209708 · Cited by 92
“In fact, a number of studies have shown an inactivation of enzymes involved in Kreb’s cycle and a consequent dysfunction of oxidative phosphorylation in human tumors (Pollard et al., 2003, 2005; Morris et al., 2004).”
BackgroundRare insights into cancer biology
Adam, J., Yang, M., Soga, T., & Pollard, P. J. (2013) · Oncogene · doi:10.1038/onc.2013.222 · Cited by 93
Self-citationMetabolic defects provide a spark for the epigenetic switch in cancer
Hitchler, M. J., & Domann, F. E. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.04.010 · Cited by 91
“For example, Complex II defects increase cellular levels of succinate, and stabilize HIF-1α through substrate inhibition of α-ketoglutarate requiring prolyl hydroxylases [142,143].”
Transcriptional Regulation of Energy Metabolism in Cancer Cells
Rodríguez‐Enríquez, S., Marín‐Hernández, Á., Gallardo‐Pérez, J. C., Pacheco-Velázquez, S. C., Belmont-Díaz, J., Robledo‐Cadena, D. X., Vargas-Navarro, J. L., de la Peña, N. A. C., Saavedra, E., & Moreno‐Sánchez, R. (2019) · Cells · doi:10.3390/cells8101225 · Cited by 92
“Under normoxia, glycolytic flux increases in cancer cells, leading to elevated cytosolic pyruvate and lactate levels, which are PH competitive inhibitors versus 2-OG [11]: other PH inhibitors such as succinate and fumarate may also be elevated in cancer cells [12,13].”
BackgroundMetabolic tricks of cancer cells
Hönigová, K., Navrátil, J., Peltanová, B., Polanska, H. H., Raudenská, M., & Masařík, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188705 · Cited by 91
Qin, N., de Cubas, A. A., García-Martín, R., Richter, S., Peitzsch, M., Menschikowski, M., Lenders, J. W. M., Timmers, H. J. L. M., Mannelli, M., Opocher, G., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28868 · Cited by 92
Laurenti, G., & Tennant, D. A. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160099 · Cited by 91
“HIF-1α is therefore stabilized and, as a result, high levels of HIF-1α transcription factor and its target genes have been observed in vitro and in patients affected by HLRCC leiomyomas [31].”
BackgroundAdvances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research
Ooi, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.016 · Cited by 90
“[30] These results point to several inconsistencies as to why FH mutation is more effective at activating HIF1A in fibroids as opposed to renal tumors, and why SDH mutant HPGL tumors show more consistent HIF1A activation.[30]”
ResultInfluentialParagangliomas/Pheochromocytomas: Clinically Oriented Genetic Testing
Martins, R., & Bugalho, M. J. (2014) · International Journal of Endocrinology · doi:10.1155/2014/794187 · Cited by 90
Mitochondrial dysfunction in cancer chemoresistance
Guaragnella, N., Giannattasio, S., & Moro, L. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.027 · Cited by 90
“FH (loss-of-function) Fumarate Decreased flux of metabolites through the Krebs cycle Impaired oxidative metabolism Increased glutamine uptake and lactate production Accumulation of fumarate-derived argininosuccinate Acquired auxotrophy for arginine Bilirubin excretion Inhibition of α-KGdependent dioxygenases (KDMs, TE…”
Modern Nuclear Imaging for Paragangliomas: Beyond SPECT
Taïeb, D., Neumann, H. P. H., Rubello, D., AL-NAHHAS, A. M., Guillet, B. A., & Hindié, E. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.098152 · Cited by 90
Von Hippel-Lindau disease and endocrine tumour susceptibility
Woodward, E. R., & Maher, E. R. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.00683 · Cited by 87
“…SDHB and SDHD gene carriers demonstrate evidence of HIF activation and over-expression of hypoxia-inducible genes (Gimenez-Roqueplo et al. 2001, Pollard et al. 2005) and SDH inactivation has been shown in vitro to inhibit HIF-a prolyl hydroxylases leading to stabilisation and activation of…”
BackgroundHypoxia-Inducible Histone Lysine Demethylases: Impact on the Aging Process and Age-Related Diseases
Antero, S., Kai, K., & Anu, K. (2016) · Aging and disease · doi:10.14336/ad.2015.0929 · Cited by 89
“[36] reported that the germline mutations of fumarate hydratase (FH) and SDHB, -C, and -D genes provoked the accumulation of fumarate and succinate into cultured cells and induced the over-expression of HIF-1α, which promoted the appearance of different types of cancers.”
BackgroundPseudohypoxic Pathways in Renal Cell Carcinoma
Bratslavsky, G., Sudarshan, S., Neckers, L., & Linehan, W. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2510 · Cited by 89
Ge, X. Q., Li, M., Yin, J., Shi, Z., Fu, Y. S., Zhao, N., Chen, H., Meng, L., Li, X., Hu, Z., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.01.029 · Cited by 88
Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism
Pollard, P. J., Yang, M., Su, H., Soga, T., & Kranc, K. R. (2014) · Hypoxia · doi:10.2147/hp.s47968 · Cited by 87
Self-citationClinical and molecular progress in hereditary paraganglioma: Figure 1
Baysal, B. E. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.058560 · Cited by 86
“HIF1-a and some of its transcriptional targets are upregulated both in PGL and HLRCC tumours.(44)”
BackgroundNitrogen anabolism underlies the importance of glutaminolysis in proliferating cells
Meng, M., Chen, S., Lao, T., Liang, D., & Sang, N. (2010) · Cell Cycle · doi:10.4161/cc.9.19.13139 · Cited by 86
The metabolic cooperation between cells in solid cancer tumors
Icard, P., Kafara, P., Steyaert, J., Schwartz, L. H., & Lincet, H. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.06.002 · Cited by 87
Inborn disorders of the malate aspartate shuttle
Broeks, M. H., van Karnebeek, C., Wanders, R. J. A., Jans, J. J. M., & Verhoeven‐Duif, N. M. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12402 · Cited by 86
Metabolic alterations and vulnerabilities in hepatocellular carcinoma
Tenen, D. G., Chai, L., & Tan, J. L. (2020) · Gastroenterology report · doi:10.1093/gastro/goaa066 · Cited by 85
“tend to gain loss-of-function mutations [41, 42].”
Metabolism of Kidney Cancer: From the Lab to Clinical Practice
Sudarshan, S., Karam, J. A., Brugarolas, J., Thompson, R. H., Uzzo, R. G., Rini, B. I., Margulis, V., Patard, J., Escudier, B. J., & Linehan, W. M. (2012) · European Urology · doi:10.1016/j.eururo.2012.09.054 · Cited by 85
“As expected, tumors that lack FH have elevated levels of fumarate [54].”
BackgroundThe Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity
Scagliola, A., Mainini, F., & Cardaci, S. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7974 · Cited by 84
“…genetic hits: (i) an inactivating germline mutation and (ii) the subsequent loss of heterozygosity, caused by the mutation (usually deletion) of the second allele in tumor cells, resulting in a complete deficiency of the enzyme activity and abnormal accumulation of succinate in the tumor (36, 87).”
BRCA1 Induces Major Energetic Metabolism Reprogramming in Breast Cancer Cells
Privat, M., Radosevic‐Robin, N., Aubel, C., Cayre, A., Penault-Llorca, F. M., Marceau, G., Sapin, V., Bignon, Y., & Morvan, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102438 · Cited by 84
“Succinate, which accumulates in BRCA1-mutated cells as a result of low SDH level, can exit the mitochondria and activate HIF1a [37,38].”
BackgroundHypoxia-inducible factor (HIF) network: insights from mathematical models
Cavadas, M. A., Nguyen, L. K., & Cheong, A. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-42 · Cited by 74
“The additional complexity can be encoded by changes in the molecular microenvironment [25,28,38,40-42] and brought about by feedback loops [25,28,30,31,50].”
BackgroundLussey‐Lepoutre, C., Bellucci, A., Morin, A., Buffet, A., Amar, L., Janin, M., Ottolenghi, C., Zinzindohoué, F., Autret, G., Burnichon, N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1576 · Cited by 85
“Succinate concentrations in the millimolar range—4 to 500 micromoles per gram depending on studies and procedures— have been reported in SDHx-mutated PPGL tumors, an increase of up to 100-fold compared with non-SDHx–mutated PPGL tumors (19, 21, 23).”
BackgroundMethodSelf-citationAMPK: mediating the metabolic effects of salicylate-based drugs?
Steinberg, G. R., Dandapani, M., & Hardie, D. G. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.06.002 · Cited by 83
Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel
Wojtovich, A. P., Smith, C. O., Haynes, C. M., Nehrke, K. W., & Brookes, P. S. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.12.007 · Cited by 83
“In support of this mechanism as a link between complex II mutations and cancer, increased cytoplasmic succinate levels have been confirmed in SDH–A [21], –B [22], –C and –D [11,23] mutants in association with an activated HIF pathway (see also[24,25]).”
BackgroundMitochondria and reactive oxygen species in renal cancer
Hervouet, É., Simonnet, H., & Godinot, C. (2007) · Biochimie · doi:10.1016/j.biochi.2007.03.010 · Cited by 83
Gómez, V., Eykyn, T. R., Mustapha, R., Flores‐Borja, F., Male, V. H., Barber, P. R., Patsialou, A., Green, R. J., Panagaki, F., Li, C. W., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aax4585 · Cited by 83
Therapeutic Manipulation of the HIF Hydroxylases
Nagel, S., Talbot, N. P., Mecinović, J., Smith, T. G., Buchan, A. M., & Schofield, C. J. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2711 · Cited by 86
“The concentration of these intermediates may reach sufficiently high levels to inhibit the HIF hydroxylases in some cells, in particular in tumors where mutations can lead to elevated levels of succinate and fumarate (152).”
Koivunen, P., & Laukka, T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2721-8 · Cited by 82
Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate
Goncalves, J., Moog, S., Morin, A., Gentric, G., Müller, S., Morrell, A. P., Kľučková, K., Stewart, T. J., Andoniadou, C. L., Lussey‐Lepoutre, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2936 · Cited by 81
Mason, E. F., & Hornick, J. L. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.86 · Cited by 81
Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy
Pfaffenroth, E. C., & Linehan, W. M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.6.779 · Cited by 80
“demonstrated strong HIF-1 expression in HLRCC renal tumors [87] .”
BackgroundAshrafian, H., O'Flaherty, L., Adam, J., Steeples, V., Chung, Y.-L., East, P., Vanharanta, S., Lehtonen, H., Nye, E., Hatipoglu, E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1949 · Cited by 72
Self-citationSuccinate Dehydrogenase-deficient Tumors: Diagnostic Advances and Clinical Implications
Barletta, J. A., & Hornick, J. L. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31825c6bc6 · Cited by 79
Zhang, Z., Yan, J., & Shi, H. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.012 · Cited by 79
Genetic bases of pheochromocytoma and paraganglioma
Cascón, A., Calsina, B., Monteagudo, M., Mellid, S., Díaz‐Talavera, A., Currás-Freixes, M., & Robledo, M. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0167 · Cited by 78
Mutation of SDHB is a Cause of Hypoxia-Related High-Altitude Paraganglioma
Cerecer-Gil, N. Y., Figuera, L. E., Llamas, F. J., Lara, M., Escamilla, J. G., Ramos, R., Estrada, G., Hussain, A. K., Gaal, J., Korpershoek, E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0637 · Cited by 71
“Oxygen normally facilitates the degradation of HIF-1 due to hydroxylation by oxygen-dependent PHD and targeting of a VHL-E3 ubiquitin-protein ligase degradation complex.”
BackgroundInfluentialChiaradonna, F., Gaglio, D., Vanoni, M., & Alberghina, L. (2006) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2006.08.001 · Cited by 77
“Germline heterozygous mutations in nuclear genes encoding subunits of mitochondrial complex II (succinate-ubiquinone oxydoreductase, composed of four subunits – SDHA, SDHB, SDHC and SDHD – and involved in electron transport and in tricarboxylic-acid cycle) cause inherited tumoral syndromes [46,48,57–59], while homozyg…”
BackgroundDownregulation of PCK2 remodels tricarboxylic acid cycle in tumor-repopulating cells of melanoma
Luo, S., Li, Y., Ma, R., Liu, J., Xu, P., Zhang, H.-B., Tang, K., Ma, J., Liu, N., Zhang, Y., et al. (2017) · Oncogene · doi:10.1038/onc.2016.520 · Cited by 78
Lendvai, N., Pawlosky, R., Bullova, P., Eisenhofer, G., Patocs, A., Veech, R. L., & Pacak, K. (2014) · Endocrinology · doi:10.1210/en.2013-1549 · Cited by 76
Lima, A. R., Pinto, J., Amaro, F., Bastos, M. D. L., Carvalho, M. C., & de Pinho, P. G. (2021) · Metabolites · doi:10.3390/metabo11030181 · Cited by 76
“, paraganglioma, pheochromocytoma or kidney cancers [78]) with mutation in the enzymes succinate dehydrogenase (SDH) and fumarate hydratase (FH), respectively [49,80].”
BackgroundInfluentialBarth, S., Edlich, F., Berchner‐Pfannschmidt, U., Gneuss, S., Jahreis, G., Hasgall, P. A., Fandrey, J., Wenger, R. H., & Camenisch, G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.032631 · Cited by 75
Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis
Barger, J. F., & Plas, D. R. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-10-0106 · Cited by 68
“org measurement of increased succinate and HIF-1a levels in primary paraganglioma tumor samples (Pollard et al. 2005).”
Inter‐connection between mitochondria and HIFs
Tormos, K. V., & Chandel, N. S. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01031.x · Cited by 74
“Another TCA metabolite that regulates HIF activation under normoxia is fumarate [47].”
BackgroundEnzymatic features of the glucose metabolism in tumor cells
Herling, A., König, M., Bulik, S., & Holzhütter, H. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08174.x · Cited by 75
Koeman, J. M., Russell, R. C., Tan, M., Petillo, D., Westphal, M., Koelzer, K., Metcalf, J. L., Zhang, Z., Matsuda, D., Dykema, K. J., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000176 · Cited by 74
“The disruption of HIF activity has been associated with kidney cancer related to VHL disease, sporadic clear cell RCC, and hereditary papillary RCC [38,41,42].”
BackgroundMetabolic Mechanisms of Epigenetic Regulation
Meier, J. L. (2013) · ACS Chemical Biology · doi:10.1021/cb400689r · Cited by 73
Marden, J. H. (2013) · Molecular Ecology · doi:10.1111/mec.12534 · Cited by 74
“…in SDH, FDH or IDH have increased metabolite concentrations, constitutive activation of the HIF pathway (pseudohypoxia: GimenezRoqueplo et al. 2001; Pollard et al. 2005; Selak et al. 2005; Baysal et al. 2007; Smith et al. 2007; Bellance et al. 2009; Zhao et al. 2009; Puissegur et al. 2011) and…”
BackgroundManganese Superoxide Dismutase: Structure, Function, and Implications in Human Disease
Grujičić, J., & Allen, A. R. (2025) · Antioxidants · doi:10.3390/antiox14070848 · Cited by 73
A Systems Approach to Predict Oncometabolites via Context-Specific Genome-Scale Metabolic Networks
Nam, H., Campodonico, M. A., Bordbar, A., Hyduke, D. R., Kim, S., Zielinski, D. C., & Palsson, B. Ø. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003837 · Cited by 73
Deciphering metabolic rewiring in breast cancer subtypes
Ogrodzinski, M. P., Bernard, J. J., & Lunt, S. Y. (2017) · Translational research · doi:10.1016/j.trsl.2017.07.004 · Cited by 73
Máximo, V., Lima, J. P., Soares, P., & Sobrinho-Simões, M. A. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0766-2 · Cited by 73
“1) and although there is no clear overlap of the tumour spectrum associated with SDH and FH mutations (possibly with the exception of renal cell carcinoma), both neoplastic syndromes give rise to tumours showing increased microvessel density and activation of the hypoxia pathway [48].”
BackgroundMito-Nuclear Communication by Mitochondrial Metabolites and Its Regulation by B-Vitamins
Janssen, J. J. E., Grefte, S., Keijer, J., & de Boer, V. C. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00078 · Cited by 72
“…by stabilizing HIF1A via EGLN inhibition (Figure 3) (Gimenez-Roqueplo et al., 2001; Briere et al., 2005; Dahia et al., 2005; Isaacs et al., 2005; Pollard et al., 2005; Selak et al., 2005; Koivunen et al., 2007), although succinate was also found to alter EGLN activity via a HIF-independent…”
BackgroundAntonio, K. L., Valdez, M. M. N., MERCADO-ASIS, L. B., Taïeb, D., & Pacák, K. (2020) · Gland Surgery · doi:10.21037/gs.2019.10.25 · Cited by 73
“The resulting higher succinate:fumarate ratio enables differentiation from non-SDHx PGLs making it a very useful metabolic marker (90,94,95).”
Background
Metadata
- Authors
- Pollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., Hargreaves, I. P., Heales, S. J., Chung, Y. L., Griffiths, J. R., Dalgleish, A., McGrath, J. A., Gleeson, M. J., Hodgson, S. V., Poulsom, R., Rustin, P., & Tomlinson, I. P. M.
- Affiliations
- St Thomas' Hospital (GB)
- Cancer Research UK (GB)
- Sheffield Children's Hospital (GB)
- University Hospital of Wales (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- St George's Hospital (GB)
- Guy's Hospital (GB)
- Inserm (FR)
- Corresponding author
- Pollard, P.J.
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-29
- Volume
- 14
- Issue
- 15
- Pages
- 2231-2239
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2136749294
- Cited by
- 865
- References
- 39
- Citations by year
- 2026: 28 · 2025: 26 · 2024: 15 · 2023: 29 · 2022: 37 · 2021: 48 · 2020: 37 · 2019: 56 · 2018: 48 · 2017: 34 · 2016: 47 · 2015: 58 · 2014: 52 · 2013: 55 · 2012: 48
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Human Molecular Genetics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Funders
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- fumarate hydratase, succinate dehydrogenase, Krebs cycle intermediates, fumarate accumulation, succinate accumulation, HIF-1α stabilization, hereditary leiomyomatosis and renal cell carcinoma, paraganglioma, pheochromocytoma, leiomyoma, microvessel density, vascular endothelial growth factor, reactive oxygen species
- MeSH terms
- Carcinoma, Renal Cell, Citric Acid Cycle, Female, Fumarate Hydratase, Humans, Leiomyoma, Neoplasms, Paraganglioma, Succinate Dehydrogenase, Tumor Cells, Cultured, Germ-Line Mutation, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.